Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative amyloid disorder therapeutics - BSIM Therapeutics

Next Previous
Search
Drug Profile

Research programme: neurodegenerative amyloid disorder therapeutics - BSIM Therapeutics

Alternative Names: ATTR EYE; ATTR HEART; ATTR PNS/CNS

Latest Information Update: 01 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BSIM2
  • Developer BSIM Therapeutics; BSIM2
  • Class Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Amyloid polyneuropathy; Familial amyloidosis

Highest Development Phases

  • Research Cardiomyopathies; Cerebrovascular disorders; Eye disorders; Familial amyloid neuropathy
  • No development reported Alzheimer's disease

Most Recent Events

  • 01 Oct 2021 neurodegenerative amyloid disorder therapeutics is still in early research for familial amyloid neuropathy, familial amyloidotic cardiomyopathy and cerebrovascular and eye disorders associated with transthyretin-related amyloidosis (BSIM Therapeutics pipeline, October 2021)
  • 01 Oct 2021 BSIM Therapeutics files for patent protection for AT50, AT40, AT09 and NT60 technologies as of October 2021 (BSIM Therapeutics pipeline; October 2021)
  • 01 Oct 2021 Early research in Cerebrovascular disorders in Portugal (unspecified route) as of October 2021 (BSIM Therapeutics pipeline, October 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top